Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity

Published:2024-07-17 Issue:8 Volume:33 Page:757-773
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Gaffey Robert H.¹,Takyi Afua K.¹,Shukla Alpana¹

Affiliation:

1. Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Weill Cornell Medicine, New York, NY, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2024.2377319

Reference145 articles.

1. World Obesity Atlas. 2023.

2. An update on peptide-based therapies for type 2 diabetes and obesity

3. GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy

4. The Origin and Understanding of the Incretin Concept

5. New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP